EMEA-002016-PIP05-23 - paediatric investigation plan

Alpelisib
PIPHuman

Key facts

Invented name
Piqray
Active Substance
Alpelisib
Therapeutic area
Congenital, familial and genetic disorders
Decision number
P/0090/2024
PIP number
EMEA-002016-PIP05-23
Pharmaceutical form(s)
  • Film-coated tablet
  • Age-appropriate formulation
Condition(s) / indication(s)
Treatment of lymphatic malformations associated with a PIK3CA mutation
Route(s) of administration
Oral use
Contact for public enquiries

Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 613241111

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page